Enpulse™ Pacing System: Implantable heart pacemaker that automatically adjusts electrical impulses for patients with cardiac arrhythmia.

May 2004
This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests and inquiries concerning reproduction and rights should be addressed to Commonwealth Copyright Administration, Attorney General’s Department, Robert Garran Offices, National Circuit, Canberra ACT 2600 or posted at http://www.ag.gov.au/cca

Electronic copies can be obtained from http://www.horizonscanning.gov.au

Enquiries about the content of this summary should be directed to:

HealthPACT Secretariat
Department of Health and Ageing
MDP 106
GPO Box 9848
Canberra ACT 2606
AUSTRALIA

DISCLAIMER: This summary is based on information available at the time of research and cannot be expected to cover any developments arising from subsequent improvements to health technologies. This summary is based on a limited literature search and is not a definitive statement on the safety, effectiveness or cost-effectiveness of the health technology covered.

The Commonwealth does not guarantee the accuracy, currency or completeness of the information in this summary. This summary is not intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for a health professional's advice. The Commonwealth does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information.

The production of this Horizon scanning prioritising summary was overseen by the Health Policy Advisory Committee on Technology (HealthPACT), a sub-committee of the Medical Services Advisory Committee (MSAC). HealthPACT comprises representatives from health departments in all states and territories, the Australia and New Zealand governments; MSAC and ASERNIP-S. The Australian Health Ministers’ Advisory Council (AHMAC) supports HealthPACT through funding.

This Horizon scanning prioritising summary was prepared by Adriana Parrella and Tracy Merlin from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Department of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005.
PRIORITISING SUMMARY

REGISTER ID: 000098

NAME OF TECHNOLOGY: **ENPULSE™ PACING SYSTEM**

PURPOSE AND TARGET GROUP: **IMPLANTABLE HEART PACEMAKER THAT AUTOMATICALLY ADJUSTS ELECTRICAL IMPULSES FOR PATIENTS WITH CARDIAC ARRHYTHMIA**

STAGE OF DEVELOPMENT (IN AUSTRALIA):

- [x] Yet to emerge
- [ ] Established
- [ ] Experimental
- [x] Established _but_ changed indication or modification of technique
- [ ] Investigational
- [ ] Should be taken out of use
- [ ] Nearly established

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION APPROVAL

- [x] Yes
- [ ] No

INTERNATIONAL UTILISATION:

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Trials Underway or Completed</th>
<th>Limited Use</th>
<th>Widely Diffused</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yugoslavia</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IMPACT SUMMARY:

Medtronic has developed the EnPulse™ pacing system for patients with cardiac arrhythmia.

BACKGROUND

A pacemaker is used to regulate the heartbeat of patients with a slow or irregular heartbeat (cardiac arrhythmia). An implanted generator produces electrical impulses that are conducted through leads to stimulate the heart muscle.

The EnPulse™ pacing system automatically monitors and adjusts the level of electrical impulses at regular intervals, unlike pacemakers that require manual adjustments by a physician. The American Food and Drug Administration approved the use of this pacemaker with an Internet-based remote monitoring network for cardiac devices, which is operated by the manufacturer. The network allows patients to transmit information from their pacemaker while at home or travelling, rather than making a trip to the doctor's office. Doctors can then review the
The new Medtronic EnPulse™ system is the first pacemaker capable of performing a complete set of diagnostic tests without human intervention. A previous EnPulse™ was approved in the United States in December, 2003 (Medtronic 2004). Pre-market approval for EnPulse™ Implantable Pulse Generator and Model 9991 Application Software was granted in March 2004. EnPulse™ pacemakers are indicated for use in patients who are experiencing conditions that warrant chronic cardiac pacing, including:
1) Symptomatic paroxysmal or permanent second or third-degree atrioventricular block.
2) Symptomatic bilateral bundle branch block.
3) Symptomatic paroxysmal or transient sinus node dysfunctions with or without associated atrioventricular conduction disorders.
4) Bradycardia-tachycardia syndrome.
5) Vasovagal syndromes or hypersensitive carotid sinus syndromes (FDA 2004)

EnPulse™ pacemakers are also indicated for use in patients who may benefit from rate responsive pacing to support cardiac output during varying levels of activity.

**CLINICAL NEED AND BURDEN OF DISEASE**
The number of hospital separations for ‘Cardiac Pacemaker Implantation’ in code F12Z in 2001-2 was 8,186 (AIHW 2004). The Australian National Hospital Morbidity Database listed 1,928 and 1,157 hospital separations for principal diagnoses I49.8 ‘Other specified cardiac arrhythmias’ and I49.9 ‘Cardiac arrhythmia’, unspecified respectively in the year 2001-2. There were also 691 and 2,538 hospital separations for ‘Atrioventricular block, second and third (complete) degree (principal diagnoses, I44.1 and I44.2). The number of hospital separations for supraventricular tachycardia, ventricular tachycardia, and paroxysmal tachycardia in 2001-2 was 9,408 (principal diagnoses I47.1, I47.2, I47.9).

**DIFFUSION**
Given that the total number of cardiac pacemaker implantation procedures is high, it is likely that there will be a rapid uptake of the EnPulse™.

**COMPARATORS**
Conventional pacemakers count and store the number of ‘events’ (changes in electrical activity) occurring in the atrium and/or ventricle over a specified period of time (Pollak et al, 2003). The limitation of this technology is that it reflects the pacemaker’s interpretation of events that it records. For example, it may over-sense appropriate activity or under-sense inappropriate activity that leads to paroxysmal atrial fibrillation. Follow-up manual threshold testing is necessary to objectively evaluate optimal pacemaker function. Automatic sensing may improve the detection of arrhythmias and the mechanisms that trigger the onset of arrhythmias.

**COST IMPACT**
Current MBS item fees for single implantation of chamber permanent transvenous electrode, permanent cardiac pacemaker, and dual chamber permanent transvenous electrode (MBS item numbers 38278, 38281, 38284) are $530.80, $212.30, and $695.90.

A comparison between the cost of the EnPulse™ and previous pacemaker models is currently not available from Medtronic Australia.
EFFECTIVENESS AND SAFETY ISSUES

The manufacturer has just begun trialling the EnPulse™ in 25 medical institutions worldwide (Medtronic 2004b). To date Medtronic Australia has not provided information regarding trial methodology.

The trials will evaluate:

**Atrial Capture Management** whereby the system automatically adjusts impulses to optimally stimulate the right atrium. A previous Medtronic model (Kappa) has a similar function for stimulation of the right ventricle. The EnPulse™ is the only pacemaker designed to automatically deliver adaptive threshold management in both chambers of the heart.

**Search AV +**: The EnPulse™ system uses an automatic and expanded search method intended to sense the patient’s natural heartbeats before delivering pacing therapy, which could reduce unnecessary stimulation impulses to the ventricle. Recent clinical studies have suggested that reducing this pacing stimulation may reduce the patient’s risk of developing heart failure and extending the longevity of the device (Medtronic 2004b).

**Quick Look II screen**: This new user-interface with the device will allow clinicians to look at one programmer screen during a patient’s device check appointment and instantly access complete information about the patient and device. In addition, the manufacturer will evaluate whether new trend monitoring capabilities reduce the amount of time needed to gather key information and shorten patient office visits.

ETHICAL, CULTURAL OR RELIGIOUS CONSIDERATIONS

No issues were identified/raised in the sources examined.

CONCLUSION:

There is currently limited evidence available on the safety and effectiveness of the EnPulse™. However, there is the potential for a rapid uptake of this technology in the Australian health system.

HEALTHPACT ACTION:

Therefore it is recommended that this technology be monitored.

SOURCES OF FURTHER INFORMATION:


SEARCH CRITERIA TO BE USED:
Arrhythmia/diagnosis
Atrial Fibrillation/complications/diagnosis/therapy
Atrial Fibrillation/diagnosis/therapy
Cardiac Pacing, Artificial/methods
Pacemaker, Artificial
Tachycardia/diagnosis